Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy
Hyo Song Kim(Yonsei University), Hyunki Kim(Yonsei University), Sang Kil Lee(Korea Advanced Institute of Science and Technology), Woo Jin Hyung(Sechenov University), Minkyu Jung(Cancer Research Institute), Sun Young Rha(Yonsei University), Taeil Son(The Catholic University of Korea Seoul St. Mary's Hospital), Seung‐Hoon Beom(Yonsei University), Joon Seok Lim(Yonsei University), Sung Hoon Noh(Gangnam Severance Hospital), Woong Sub Koom(Yonsei University), Sung Kwan Shin(Yonsei University), Yong Chan Lee(Yonsei University), Su‐Jin Shin(Yonsei University), Yoon Young Choi(Yonsei University), Hyun Cheol Chung(Yonsei University), Hyunsoo Chung(Seoul National University), Jae‐Ho Cheong(Yonsei University), Hyoung‐Il Kim(Yonsei University), Jun Chul Park(Yonsei University)
Cited by 61
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859